TGTX — Trading Ideas on TradingView

TG Therapeutics (TGTX) – Biotech Innovation & Global Expansion Company Overview: TG Therapeutics NASDAQ:TGTX is a biotech leader focused on novel cancer and autoimmune treatments, gaining momentum as an IBD Leaderboard and IBD 50 Top 10 Growth Stock. Key Catalysts: Regulatory Approvals & Expansion 🌍 BRIUMVI secured approvals in Europe & the UK, unlocking new revenue streams in key markets. Strong Profitability & Growth 💰 88.3% gross margin ensures sustainable reinvestment into R&D and future pipeline advancements. High-Growth Stock Recognition 📊 Technical strength is validated by its inclusion in top-performing stock lists, signaling strong investor confidence. Investment Outlook: Bullish Case: We are bullish on TGTX above $34.00-$35.00, driven by global expansion, financial strength, and biotech leadership. Upside Potential: Our price target is $55.00-$56.00, supported by continued innovation and market penetration. 🔥 TG Therapeutics – Pioneering the Future of Cancer Treatment. #TGTX #Biotech #GrowthStocks

$TGTX Stock Set For Breakout Amidst Symmetrical Triangle Pattern TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX ) a biopharmaceutical company, that focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally is set for a breakout amidst a bullish symmetrical triangle pattern. Analyst Forecast According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is an increase of 35.16% from the latest price. Important Dates The next confirmed earnings date is Monday, March 3, 2025, before market open. On How the bullish symmetrical plays out is largely incumbent on the earnings report slated for today Monday March 3, 2025 before the bell.

TGTX swing pick doubler 5 months but nearly +100% much better than 15% or 20%/year with index

TG Therapeutics (TGTX) Analysis Company Overview: TG Therapeutics NASDAQ:TGTX is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell diseases. The company's recent FDA approval of BRIUMVI for relapsing multiple sclerosis (RMS) marks a significant milestone, positioning TG Therapeutics to capitalize on a high-demand therapeutic area. Key Developments: FDA Approval of BRIUMVI: The approval of BRIUMVI for relapsing multiple sclerosis opens access to a substantial market, with nearly 1 million individuals in the U.S. affected by RMS. This provides a significant revenue opportunity, with BRIUMVI offering a new treatment option that has shown favorable efficacy, safety, and convenient dosing compared to existing therapies. Positive Market Reception: CEO Michael S. Weiss has expressed strong confidence in BRIUMVI's potential, noting positive feedback from both healthcare providers and patients. The drug's unique value proposition lies in its twice-yearly dosing, which is more convenient than the monthly or quarterly regimens offered by competitors, enhancing patient compliance and satisfaction. Pipeline and Future Growth: The successful launch of BRIUMVI is a testament to TG Therapeutics' ability to introduce novel treatments. This sets a strong foundation for future developments in B-cell disease therapies, as the company explores additional indications and expands its pipeline. BRIUMVI's performance in the market could pave the way for further advancements in TG Therapeutics' product offerings. Investment Outlook: Bullish Outlook: We are bullish on TGTX above the $21.00-$22.00 range, driven by the strong initial reception of BRIUMVI and its potential to capture a significant share of the RMS market. Upside Potential: Our price target for TG Therapeutics is set at $34.00-$35.00, reflecting the expected revenue growth from BRIUMVI and the company's strategic positioning in the biopharma sector. 🚀 TGTX—Leading the Way in B-cell Disease Therapies! #BiopharmaInnovation #MultipleSclerosis #NewTreatmentOptions

TG Therapeutics. Boom! TGTX We are moving up. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!

TG Therapeutics $TGTX is on the top $TGTX is hitting the 5 years high. It did %65 in this week so far. RSI is still 66 on weekly and needs more for breakout. It may pull back before continues

EYPT | Range bound Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 - $1.87 is approximately $0.45 of profit both ways up (~20%+) until EYPT confirms they are adhering to terms of loan with CRG. Weekly MACD and Stochastics have divergence with stock price. This could infer spring board type action on good news (break below range could cause problems). Previous quarter showed that $EYPT was on track w/ meeting terms of CRG loan agreement. positive earning/ ER beat should help satisfy some hedge funds/ big $ investors. I remain cautiously optimistic. $EYPT could potentially come and test lows of the range within next week. I am looking to use this as a way to add to current position/ swing trade it to highs and lower cost basis on my long-position. **On the other hand, falling below this range could cause knee jerk reaction/ selloff. I am going to be watching this carefully. Tip # 7: When trading, It is very important to have a game plan. It is good practice to establish rules to your system (i.e. do you buy in increments?, at what point do you not like the investment anymore? how long are you willing to hold?). - Please Like and Follow for trade ideas & so I can continue to chart and build my reputation. Thank you in advance =) Have a Twitter? check out my page for more: @volatilitywatch Disclosure: I am long EYPT. This is not a note to buy or sell. Please do your homework before investing. //----------------------------------------------------------------------------------- Check out current trade in TGTX =) #BULLISH

Swing idea: Possible short opportunity for a couple of points If the 100 ema holds as resistance and price start to turns. Place sell below a red candle that is touching buy/sell zone. Targets are Fib levels. Stop loss will be above the last swing-high after entry Just a short swing trade idea (all technical no fundamentals)

TGTX swing let's see what happens next week before conference